BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ConjuGon, Inc. Appoints Guillermo Herrera To Board Of Directors


10/19/2005 5:12:23 PM

MADISON, Wis., Dec. 7 /PRNewswire/ -- ConjuGon(TM), a biotechnology company developing fundamentally new treatments for antibiotic-resistant bacterial infections, announced today that it has appointed Guillermo Herrera to its Board of Directors.

Mr. Herrera spent more than 24 years with Abbott Laboratories where his positions included Senior Vice President of International Operations, President of Abbott International. Mr. Herrera held other senior leadership positions, including Vice President, European Operations, and Vice President, Latin American and Canada Operations. He was elected an Abbott Corporate Vice President in 1996. Mr. Herrera currently is a Principal of the Rosetta Group, LLC (Lake Forest, Illinois), a biotechnology investment fund.

"Guillermo has great insights and expertise from his years working in proprietary pharmaceuticals," said ConjuGon CEO Christopher Price. "His experience in all aspects of pharmaceutical development, operations and marketing will be invaluable assets for ConjuGon. The ConjuGon Board of Directors, the management team, and I all look forward to working closely with Guillermo as we continue to develop our technology."

"The problem of antibiotic resistance is getting worse and worse every day," stated Mr. Herrera. "Fundamentally new technologies are critically needed to overcome a serious public health threat. I'm excited about working with ConjuGon in helping it bring new health care solutions to patients."

ConjuGon is developing fundamentally new technologies to combat the growing epidemic of antibioticresistant bacteria. Antibiotic resistance is a medical crisis, globally responsible for hundreds of thousands of deaths each year. ConjuGon's core technology is a new way to kill multi-drug resistant bacteria. The company is located in the MG&E Innovation Center in Madison, Wisconsin.

ConjuGon, Inc.

CONTACT: Sal Braico of ConjuGon, Inc., +1-608-441-2890,sbraico@conjugon.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES